ketorolac and lidocaine

Small molecule

JJohns Hopkins University

ketorolac and lidocaine is one of 35 small molecule programs targeting Abortion. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AbortionActive, not recruiting

AbortionPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

97 competitors in Abortion

#DrugCompanyPhaseTrials

Mifeprex

DDanco

Approved

22 2

Prometrium

Ferring

Approved

2 3

Versed

CConrado Roberto Hoffmann Filho

Approved

1 4

Advil

KKenvue Brands

Phase 3

5 5

Oxycontin

PProtega

Phase 3

1 6

Dostinex

Pfizer

Phase 2

2 7

Enoxaparine

Sanofi

Phase 3

1 8

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Phase 3

1 9

Spravato

WWim Janssens

Phase 2

1 10

Anerem

AAcacia Pharma Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Abortion1 trial

Paracervical Block in First Trimester Surgical Abortions

Completed·JJohns Hopkins University·Phase 2/3·NCT00617097·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ketorolac and lidocaine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ketorolac and lidocaine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ketorolac and lidocaine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johns Hopkins University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: JJohns Hopkins University

ketorolac and lidocaine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Abortion1 trial

References

Drug Info

Quick Facts

Related News